APO Research
Talk to an analyst

APO RESEARCH · REPORT

Drugs for Dermatophytosis

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Drugs for Dermatophytosis Market Outlook and Growth Opportunities 2026

22 December 2025199 pages

Choose your research edition.

Industry ResearchDrugs for Dermatophytosis Industry Research Report 2026112 pages · $2,950 USDIndustry Growth & TrendsGlobal Drugs for Dermatophytosis Industry Growth and Trends Forecast to 203285 pages · $3,450 USDMarket StructureGlobal Drugs for Dermatophytosis Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032182 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Drugs for Dermatophytosis Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal Drugs for Dermatophytosis Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Drugs for Dermatophytosis market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Drugs for Dermatophytosis is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Drugs for Dermatophytosis is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Drugs for Dermatophytosis is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Drugs for Dermatophytosis market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Drugs for Dermatophytosis market include Astellas Pharma, Enzon Pharmaceuticals, Sanofi-Aventis, Bayer, GSK, Pfizer, Merck, Novartis and Abbott, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Drugs for Dermatophytosis market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Drugs for Dermatophytosis and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Drugs for Dermatophytosis revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Drugs for Dermatophytosis market.

Drugs for Dermatophytosis Segment by Company

Astellas Pharma

Enzon Pharmaceuticals

Sanofi-Aventis

Bayer

GSK

Pfizer

Merck

Novartis

Abbott

Drugs for Dermatophytosis Segment by Type

Rx

OTC

Drugs for Dermatophytosis Segment by Application

Hospital

Clinic

Other

Drugs for Dermatophytosis Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Drugs for Dermatophytosis status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Drugs for Dermatophytosis key companies, revenue, market share, and recent developments.

3. To split the Drugs for Dermatophytosis breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Drugs for Dermatophytosis market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Drugs for Dermatophytosis significant trends, drivers, influence factors in global and regions.

6. To analyze Drugs for Dermatophytosis competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Drugs for Dermatophytosis market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Drugs for Dermatophytosis and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Drugs for Dermatophytosis.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Drugs for Dermatophytosis industry.

Chapter 3: Detailed analysis of Drugs for Dermatophytosis company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Drugs for Dermatophytosis in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Drugs for Dermatophytosis in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Drugs for Dermatophytosis Industry Trends Table 2. Drugs for Dermatophytosis Industry Drivers Table 3. Drugs for Dermatophytosis Industry Opportunities and Challenges Table 4. Drugs for Dermatophytosis Industry Restraints Table 5. Global Drugs for Dermatophytosis Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Drugs for Dermatophytosis Revenue Share by Company (2021-2026) Table 7. Global Drugs for Dermatophytosis Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Drugs for Dermatophytosis Key Company Manufacturing Base & Headquarters Table 9. Global Drugs for Dermatophytosis Company, Product Type & Application Table 10. Global Drugs for Dermatophytosis Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Drugs for Dermatophytosis by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Rx Table 15. Significant Companies of OTC Table 16. Global Drugs for Dermatophytosis Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Drugs for Dermatophytosis Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global Drugs for Dermatophytosis Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global Drugs for Dermatophytosis Sales Value Share by Type (2021-2026) Table 20. Global Drugs for Dermatophytosis Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Hospital Table 22. Significant Companies of Clinic Table 23. Significant Companies of Other Table 24. Global Drugs for Dermatophytosis Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Drugs for Dermatophytosis Sales Value by Application (2021-2026) & (US$ Million) Table 26. Global Drugs for Dermatophytosis Sales Value by Application (2027-2032) & (US$ Million) Table 27. Global Drugs for Dermatophytosis Sales Value Share by Application (2021-2026) Table 28. Global Drugs for Dermatophytosis Sales Value Share by Application (2027-2032) Table 29. Global Drugs for Dermatophytosis Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Drugs for Dermatophytosis Sales Value by Region (2021-2026) & (US$ Million) Table 31. Global Drugs for Dermatophytosis Sales Value Share by Region (2021-2026) Table 32. Global Drugs for Dermatophytosis Sales Value by Region (2027-2032) & (US$ Million) Table 33. Global Drugs for Dermatophytosis Sales Value Share by Region (2027-2032) Table 34. Global Drugs for Dermatophytosis Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Drugs for Dermatophytosis Sales Value by Country (2021-2026) & (US$ Million) Table 36. Global Drugs for Dermatophytosis Sales Value Market Share by Country (2021-2026) Table 37. Global Drugs for Dermatophytosis Sales Value by Country (2027-2032) & (US$ Million) Table 38. Global Drugs for Dermatophytosis Sales Value Market Share by Country (2027-2032) Table 39. Astellas Pharma Company Information Table 40. Astellas Pharma Business Overview Table 41. Astellas Pharma Drugs for Dermatophytosis Revenue (US$ Million) and Gross Margin (2021-2026) Table 42. Astellas Pharma Drugs for Dermatophytosis Product Portfolio Table 43. Astellas Pharma Recent Development Table 44. Enzon Pharmaceuticals Company Information Table 45. Enzon Pharmaceuticals Business Overview Table 46. Enzon Pharmaceuticals Drugs for Dermatophytosis Revenue (US$ Million) and Gross Margin (2021-2026) Table 47. Enzon Pharmaceuticals Drugs for Dermatophytosis Product Portfolio Table 48. Enzon Pharmaceuticals Recent Development Table 49. Sanofi-Aventis Company Information Table 50. Sanofi-Aventis Business Overview Table 51. Sanofi-Aventis Drugs for Dermatophytosis Revenue (US$ Million) and Gross Margin (2021-2026) Table 52. Sanofi-Aventis Drugs for Dermatophytosis Product Portfolio Table 53. Sanofi-Aventis Recent Development Table 54. Bayer Company Information Table 55. Bayer Business Overview Table 56. Bayer Drugs for Dermatophytosis Revenue (US$ Million) and Gross Margin (2021-2026) Table 57. Bayer Drugs for Dermatophytosis Product Portfolio Table 58. Bayer Recent Development Table 59. GSK Company Information Table 60. GSK Business Overview Table 61. GSK Drugs for Dermatophytosis Revenue (US$ Million) and Gross Margin (2021-2026) Table 62. GSK Drugs for Dermatophytosis Product Portfolio Table 63. GSK Recent Development Table 64. Pfizer Company Information Table 65. Pfizer Business Overview Table 66. Pfizer Drugs for Dermatophytosis Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. Pfizer Drugs for Dermatophytosis Product Portfolio Table 68. Pfizer Recent Development Table 69. Merck Company Information Table 70. Merck Business Overview Table 71. Merck Drugs for Dermatophytosis Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Merck Drugs for Dermatophytosis Product Portfolio Table 73. Merck Recent Development Table 74. Novartis Company Information Table 75. Novartis Business Overview Table 76. Novartis Drugs for Dermatophytosis Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Novartis Drugs for Dermatophytosis Product Portfolio Table 78. Novartis Recent Development Table 79. Abbott Company Information Table 80. Abbott Business Overview Table 81. Abbott Drugs for Dermatophytosis Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. Abbott Drugs for Dermatophytosis Product Portfolio Table 83. Abbott Recent Development Table 84. Research Programs/Design for This Report Table 85. Authors List of This Report Table 86. Secondary Sources Table 87. Primary Sources List of Figures Figure 1. Drugs for Dermatophytosis Product Image Figure 2. Global Drugs for Dermatophytosis Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Drugs for Dermatophytosis Market Size (2021-2032) & (US$ Million) Figure 4. Global Drugs for Dermatophytosis Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Rx Image Figure 8. OTC Image Figure 9. Global Drugs for Dermatophytosis Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Drugs for Dermatophytosis Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global Drugs for Dermatophytosis Sales Value Share by Type (2021-2032) Figure 12. Hospital Image Figure 13. Clinic Image Figure 14. Other Image Figure 15. Global Drugs for Dermatophytosis Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Drugs for Dermatophytosis Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Drugs for Dermatophytosis Sales Value Share by Application (2021-2032) Figure 18. Global Drugs for Dermatophytosis Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 19. Global Drugs for Dermatophytosis Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 20. North America Drugs for Dermatophytosis Sales Value (2021-2032) & (US$ Million) Figure 21. North America Drugs for Dermatophytosis Sales Value Share by Country (%), 2025 VS 2032 Figure 22. Europe Drugs for Dermatophytosis Sales Value (2021-2032) & (US$ Million) Figure 23. Europe Drugs for Dermatophytosis Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Asia-Pacific Drugs for Dermatophytosis Sales Value (2021-2032) & (US$ Million) Figure 25. Asia-Pacific Drugs for Dermatophytosis Sales Value Share by Country (%), 2025 VS 2032 Figure 26. South America Drugs for Dermatophytosis Sales Value (2021-2032) & (US$ Million) Figure 27. South America Drugs for Dermatophytosis Sales Value Share by Country (%), 2025 VS 2032 Figure 28. Middle East & Africa Drugs for Dermatophytosis Sales Value (2021-2032) & (US$ Million) Figure 29. Middle East & Africa Drugs for Dermatophytosis Sales Value Share by Country (%), 2025 VS 2032 Figure 30. USA Drugs for Dermatophytosis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 31. USA Drugs for Dermatophytosis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 32. USA Drugs for Dermatophytosis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 33. Canada Drugs for Dermatophytosis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. Canada Drugs for Dermatophytosis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. Canada Drugs for Dermatophytosis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Mexico Drugs for Dermatophytosis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Mexico Drugs for Dermatophytosis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Mexico Drugs for Dermatophytosis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Germany Drugs for Dermatophytosis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Germany Drugs for Dermatophytosis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Germany Drugs for Dermatophytosis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. France Drugs for Dermatophytosis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. France Drugs for Dermatophytosis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. France Drugs for Dermatophytosis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. U.K. Drugs for Dermatophytosis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. U.K. Drugs for Dermatophytosis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. U.K. Drugs for Dermatophytosis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Italy Drugs for Dermatophytosis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Italy Drugs for Dermatophytosis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Italy Drugs for Dermatophytosis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Spain Drugs for Dermatophytosis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Spain Drugs for Dermatophytosis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Spain Drugs for Dermatophytosis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Russia Drugs for Dermatophytosis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Russia Drugs for Dermatophytosis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Russia Drugs for Dermatophytosis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Netherlands Drugs for Dermatophytosis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Netherlands Drugs for Dermatophytosis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Netherlands Drugs for Dermatophytosis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Nordic Countries Drugs for Dermatophytosis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Nordic Countries Drugs for Dermatophytosis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Nordic Countries Drugs for Dermatophytosis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. China Drugs for Dermatophytosis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. China Drugs for Dermatophytosis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. China Drugs for Dermatophytosis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Japan Drugs for Dermatophytosis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Japan Drugs for Dermatophytosis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Japan Drugs for Dermatophytosis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. South Korea Drugs for Dermatophytosis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. South Korea Drugs for Dermatophytosis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. South Korea Drugs for Dermatophytosis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. India Drugs for Dermatophytosis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. India Drugs for Dermatophytosis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. India Drugs for Dermatophytosis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Australia Drugs for Dermatophytosis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Australia Drugs for Dermatophytosis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Australia Drugs for Dermatophytosis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Southeast Asia Drugs for Dermatophytosis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Southeast Asia Drugs for Dermatophytosis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Southeast Asia Drugs for Dermatophytosis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Brazil Drugs for Dermatophytosis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Brazil Drugs for Dermatophytosis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Brazil Drugs for Dermatophytosis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Argentina Drugs for Dermatophytosis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Argentina Drugs for Dermatophytosis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Argentina Drugs for Dermatophytosis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Chile Drugs for Dermatophytosis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Chile Drugs for Dermatophytosis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Chile Drugs for Dermatophytosis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Colombia Drugs for Dermatophytosis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Colombia Drugs for Dermatophytosis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Colombia Drugs for Dermatophytosis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Peru Drugs for Dermatophytosis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Peru Drugs for Dermatophytosis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Peru Drugs for Dermatophytosis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Saudi Arabia Drugs for Dermatophytosis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Saudi Arabia Drugs for Dermatophytosis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Drugs for Dermatophytosis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Israel Drugs for Dermatophytosis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Israel Drugs for Dermatophytosis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Israel Drugs for Dermatophytosis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. UAE Drugs for Dermatophytosis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. UAE Drugs for Dermatophytosis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. UAE Drugs for Dermatophytosis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Turkey Drugs for Dermatophytosis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Turkey Drugs for Dermatophytosis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Turkey Drugs for Dermatophytosis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Iran Drugs for Dermatophytosis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Iran Drugs for Dermatophytosis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Iran Drugs for Dermatophytosis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Egypt Drugs for Dermatophytosis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Egypt Drugs for Dermatophytosis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Egypt Drugs for Dermatophytosis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Years Considered Figure 115. Research Process Figure 116. Key Executives Interviewed

Scope & coverage.

Types
  • Rx
  • OTC
Applications
  • Hospital
  • Clinic
  • Other
Companies covered
  • Astellas Pharma
  • Enzon Pharmaceuticals
  • Sanofi-Aventis
  • Bayer
  • GSK
  • Pfizer
  • Merck
  • Novartis
  • Abbott

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Drugs for Dermatophytosis Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Drugs for Dermatophytosis Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Drugs for Dermatophytosis Market Dynamics
  1. 2.1 Drugs for Dermatophytosis Industry Trends
  2. 2.2 Drugs for Dermatophytosis Industry Drivers
  3. 2.3 Drugs for Dermatophytosis Industry Opportunities and Challenges
  4. 2.4 Drugs for Dermatophytosis Industry Restraints
3 Drugs for Dermatophytosis Market by Company
  1. 3.1 Global Drugs for Dermatophytosis Company Revenue Ranking in 2025
  2. 3.2 Global Drugs for Dermatophytosis Revenue by Company (2021-2026)
  3. 3.3 Global Drugs for Dermatophytosis Company Ranking (2024-2026)
  4. 3.4 Global Drugs for Dermatophytosis Company Manufacturing Base and Headquarters
  5. 3.5 Global Drugs for Dermatophytosis Company Product Type and Application
  6. 3.6 Global Drugs for Dermatophytosis Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Drugs for Dermatophytosis Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Drugs for Dermatophytosis Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Drugs for Dermatophytosis Market by Type
  1. 4.1 Drugs for Dermatophytosis Type Introduction
  2. 4.1.1 Rx
  3. 4.1.2 OTC
  4. 4.2 Global Drugs for Dermatophytosis Sales Value by Type
  5. 4.2.1 Global Drugs for Dermatophytosis Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Drugs for Dermatophytosis Sales Value by Type (2021-2032)
  7. 4.2.3 Global Drugs for Dermatophytosis Sales Value Share by Type (2021-2032)
5 Drugs for Dermatophytosis Market by Application
  1. 5.1 Drugs for Dermatophytosis Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Other
  5. 5.2 Global Drugs for Dermatophytosis Sales Value by Application
  6. 5.2.1 Global Drugs for Dermatophytosis Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Drugs for Dermatophytosis Sales Value by Application (2021-2032)
  8. 5.2.3 Global Drugs for Dermatophytosis Sales Value Share by Application (2021-2032)
6 Drugs for Dermatophytosis Regional Value Analysis
  1. 6.1 Global Drugs for Dermatophytosis Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Drugs for Dermatophytosis Sales Value by Region (2021-2032)
  3. 6.2.1 Global Drugs for Dermatophytosis Sales Value by Region: 2021-2026
  4. 6.2.2 Global Drugs for Dermatophytosis Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Drugs for Dermatophytosis Sales Value (2021-2032)
  7. 6.3.2 North America Drugs for Dermatophytosis Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Drugs for Dermatophytosis Sales Value (2021-2032)
  10. 6.4.2 Europe Drugs for Dermatophytosis Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Drugs for Dermatophytosis Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Drugs for Dermatophytosis Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Drugs for Dermatophytosis Sales Value (2021-2032)
  16. 6.6.2 South America Drugs for Dermatophytosis Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Drugs for Dermatophytosis Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Drugs for Dermatophytosis Sales Value Share by Country, 2025 VS 2032
7 Drugs for Dermatophytosis Country-level Value Analysis
  1. 7.1 Global Drugs for Dermatophytosis Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Drugs for Dermatophytosis Sales Value by Country (2021-2032)
  3. 7.2.1 Global Drugs for Dermatophytosis Sales Value by Country (2021-2026)
  4. 7.2.2 Global Drugs for Dermatophytosis Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Drugs for Dermatophytosis Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Drugs for Dermatophytosis Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Drugs for Dermatophytosis Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Drugs for Dermatophytosis Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Drugs for Dermatophytosis Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Drugs for Dermatophytosis Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Drugs for Dermatophytosis Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Drugs for Dermatophytosis Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Drugs for Dermatophytosis Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Drugs for Dermatophytosis Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Drugs for Dermatophytosis Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Drugs for Dermatophytosis Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Drugs for Dermatophytosis Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Drugs for Dermatophytosis Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Drugs for Dermatophytosis Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Drugs for Dermatophytosis Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Drugs for Dermatophytosis Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Drugs for Dermatophytosis Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Drugs for Dermatophytosis Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Drugs for Dermatophytosis Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Drugs for Dermatophytosis Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Drugs for Dermatophytosis Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Drugs for Dermatophytosis Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Drugs for Dermatophytosis Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Drugs for Dermatophytosis Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Drugs for Dermatophytosis Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Drugs for Dermatophytosis Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Drugs for Dermatophytosis Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Drugs for Dermatophytosis Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Drugs for Dermatophytosis Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Drugs for Dermatophytosis Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Drugs for Dermatophytosis Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Drugs for Dermatophytosis Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Drugs for Dermatophytosis Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Drugs for Dermatophytosis Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Drugs for Dermatophytosis Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Drugs for Dermatophytosis Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Drugs for Dermatophytosis Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Drugs for Dermatophytosis Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Drugs for Dermatophytosis Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Drugs for Dermatophytosis Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Drugs for Dermatophytosis Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Drugs for Dermatophytosis Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Drugs for Dermatophytosis Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Drugs for Dermatophytosis Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Drugs for Dermatophytosis Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Drugs for Dermatophytosis Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Drugs for Dermatophytosis Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Drugs for Dermatophytosis Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Drugs for Dermatophytosis Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Drugs for Dermatophytosis Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Drugs for Dermatophytosis Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Drugs for Dermatophytosis Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Drugs for Dermatophytosis Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Drugs for Dermatophytosis Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Drugs for Dermatophytosis Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Drugs for Dermatophytosis Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Drugs for Dermatophytosis Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Drugs for Dermatophytosis Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Drugs for Dermatophytosis Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Drugs for Dermatophytosis Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Drugs for Dermatophytosis Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Drugs for Dermatophytosis Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Drugs for Dermatophytosis Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Drugs for Dermatophytosis Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Drugs for Dermatophytosis Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Drugs for Dermatophytosis Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Drugs for Dermatophytosis Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Drugs for Dermatophytosis Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Drugs for Dermatophytosis Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Drugs for Dermatophytosis Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Drugs for Dermatophytosis Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Drugs for Dermatophytosis Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Drugs for Dermatophytosis Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Drugs for Dermatophytosis Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Drugs for Dermatophytosis Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Drugs for Dermatophytosis Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Drugs for Dermatophytosis Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Drugs for Dermatophytosis Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Drugs for Dermatophytosis Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Drugs for Dermatophytosis Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Drugs for Dermatophytosis Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Drugs for Dermatophytosis Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Drugs for Dermatophytosis Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Astellas Pharma
  2. 8.1.1 Astellas Pharma Company Information
  3. 8.1.2 Astellas Pharma Business Overview
  4. 8.1.3 Astellas Pharma Drugs for Dermatophytosis Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Astellas Pharma Drugs for Dermatophytosis Product Portfolio
  6. 8.1.5 Astellas Pharma Recent Developments
  7. 8.2 Enzon Pharmaceuticals
  8. 8.2.1 Enzon Pharmaceuticals Company Information
  9. 8.2.2 Enzon Pharmaceuticals Business Overview
  10. 8.2.3 Enzon Pharmaceuticals Drugs for Dermatophytosis Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Enzon Pharmaceuticals Drugs for Dermatophytosis Product Portfolio
  12. 8.2.5 Enzon Pharmaceuticals Recent Developments
  13. 8.3 Sanofi-Aventis
  14. 8.3.1 Sanofi-Aventis Company Information
  15. 8.3.2 Sanofi-Aventis Business Overview
  16. 8.3.3 Sanofi-Aventis Drugs for Dermatophytosis Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Sanofi-Aventis Drugs for Dermatophytosis Product Portfolio
  18. 8.3.5 Sanofi-Aventis Recent Developments
  19. 8.4 Bayer
  20. 8.4.1 Bayer Company Information
  21. 8.4.2 Bayer Business Overview
  22. 8.4.3 Bayer Drugs for Dermatophytosis Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Bayer Drugs for Dermatophytosis Product Portfolio
  24. 8.4.5 Bayer Recent Developments
  25. 8.5 GSK
  26. 8.5.1 GSK Company Information
  27. 8.5.2 GSK Business Overview
  28. 8.5.3 GSK Drugs for Dermatophytosis Revenue and Gross Margin (2021-2026)
  29. 8.5.4 GSK Drugs for Dermatophytosis Product Portfolio
  30. 8.5.5 GSK Recent Developments
  31. 8.6 Pfizer
  32. 8.6.1 Pfizer Company Information
  33. 8.6.2 Pfizer Business Overview
  34. 8.6.3 Pfizer Drugs for Dermatophytosis Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Pfizer Drugs for Dermatophytosis Product Portfolio
  36. 8.6.5 Pfizer Recent Developments
  37. 8.7 Merck
  38. 8.7.1 Merck Company Information
  39. 8.7.2 Merck Business Overview
  40. 8.7.3 Merck Drugs for Dermatophytosis Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Merck Drugs for Dermatophytosis Product Portfolio
  42. 8.7.5 Merck Recent Developments
  43. 8.8 Novartis
  44. 8.8.1 Novartis Company Information
  45. 8.8.2 Novartis Business Overview
  46. 8.8.3 Novartis Drugs for Dermatophytosis Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Novartis Drugs for Dermatophytosis Product Portfolio
  48. 8.8.5 Novartis Recent Developments
  49. 8.9 Abbott
  50. 8.9.1 Abbott Company Information
  51. 8.9.2 Abbott Business Overview
  52. 8.9.3 Abbott Drugs for Dermatophytosis Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Abbott Drugs for Dermatophytosis Product Portfolio
  54. 8.9.5 Abbott Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst